García, María JoséRivero, MontserratMiranda Bautista, JoséBastón-Rey, IriaMesonero, FranciscoLeo Carnerero, EduardoCasas Deza, DiegoCagigas Fernández, CarmenMartín Cardona, AlbertEl Hajra, IsmaelHernández Aretxabaleta, NereaPérez Martínez, IsabelFuentes Valenzuela, EstebanJiménez, NuriaRubín de Célix, CristinaGutiérrez, AnaSuárez Ferrer, CristinaHuguet, José MaríaFernández Clotet, AgnesGonzález Vivó, MaríaDel Val, BlancaCastro Poceiro, JesúsMelcarne, LuigiDueñas, CarmenIzquierdo, MartaMonfort, DavidBouhmidi, AbdelRamírez De la Piscina, PatriciaRomero, EvaMolina, GemaZorrilla, JaimeCalvino Suárez, CristinaSánchez, EugeniaNuñez, AndreaSierra, OliviaCastro, BeatrizZabana, YamileGonzález Partida, IreneDe la Maza, SaioaCastaño, AndrésNájera Muñoz, RodrigoSánchez Guillén, LuisRiat Castro, MicaelaRueda, José LuisBenítez, José ManuelDelgado Guillena, PedroTardillo, CarlosPeña, ElenaFrago Larramona, SantiagoRodríguez Grau, María CarmenPlaza, RocíoPérez Galindo, PabloMartínez Cadilla, JesúsMenchén Viso, Luis AlbertoBarreiro De Acosta, ManuelSánchez Aldehuelo, RubénDe la Cruz, María DoloresLamuela, Luis JavierMarín Jiménez, IgnacioNieto García, LauraLópez San Román, AntonioHerrera, José ManuelChaparro, MaríaGisbert, Javier P.2023-06-162023-06-162021-09-262077-038310.3390/jcm10194402https://hdl.handle.net/20.500.14352/4797Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered “exposed”. The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2–2.0), urgent surgery (OR: 1.6; 95% CI: 1.2–2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1–1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3–2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97–1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03–2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.engAtribución 3.0 Españahttps://creativecommons.org/licenses/by/3.0/es/journal articlehttps://doi.org/10.3390/jcm10194402https://www.mdpi.com/2077-0383/10/19/4402/htmopen accessinflammatory bowel diseaseCrohn’s diseaseulcerative colitisanti-TNFustekinumabvedolizumabpostoperative complicationssurgerypreoperative therapyGastroenterología y hepatología3205.03 Gastroenterología